In patients with Guillain-Barré syndrome, tanruprubart yielded significant improvements in muscle strength, with patients ...

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people ...

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...

Johnson & Johnson has stopped development of an eye disease gene therapy after reviewing data from one of its key readouts for 2026. Exiting the first quarter, J&J named (PDF) data from the phase 2b ...

First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from ...

SE’s $2.2B Forte Biosciences, Inc. deal adds FB-102 to expand pipeline, but valuation & Vyvgart patent risks raise caution.

Ciprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring ...

Scientists have advanced the field of cancer treatment by leveraging the body’s immune system to recognize and target tumors.

Ciprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring ...

Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function ...

Researchers published findings on June 3, 2026, describing an oral pill that burns fat by targeting skeletal muscle and brown ...

Aldo Gucci's residence on Via della Camilluccia: two villas, 10 bedrooms, 15 rooms, 13,000 ft², swimming pool, rooftop terrace, view of the Altare della Patria, 11.5 M€.